香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 (iii) 獨立非執行董事兼提名委員會現任成員劉耀坤先生獲委任為提名委員會主席。 於上述變動後，提名委員會將由劉耀坤先生擔任主席，以及李欣梅博士及余明陽先 生擔任成員。薪酬委員會將由余明陽先生擔任主席，以及張發寶博士及劉濤女士擔 任成員。 承董事會命 梅斯健康控股有限公司 董事會主席及執行董事 張發寶博士 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 提名委員會及薪酬委員會組成變動 梅斯健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，自2025年6月 30日起，董事會提名委員會（「提名委員會」）及薪酬委員會（「薪酬委員會」）的組成調 整如下： 香港，2025年6月30日 – 1 – (i) 執行董事張發寶博士不再擔任提名委員會主席，並獲委任為薪酬委員會成員； (ii) 執行董事李欣 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本通告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 股東週年大會通告 茲通告梅斯健康控股有限公司（「本公司」）謹訂於2025年6月30日（星期一）上午十時 正假座中國上海市徐匯區宜山路光啟城辦公樓1004舉行股東週年大會，藉以考慮下 列事項： – 1 – 1. 省覽本公司截至2024年12月31日止年度的經審核綜合財務報表以及董事會報告 及核數師報告。 2. 重選張發寶博士為執行董事； 3. 重選李欣梅博士為執行董事； 4. 重選程亮先生為執行董事； 5. 重選王欣女士為非執行董事； 6. 重選劉濤女士為獨立非執行董事； 7. 授權董事會（「董事會」）釐定各董事之酬金； 8. 續聘安永會計師事務所為本公司核數師及授權董事會釐定其酬金； 9. 考慮並酌情通過（不論有否修訂）下列決議案為普通決議案： 「動議： ...

MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 此 乃 要 件 請 即 處 理 閣下對本通函任何內容或應採取之行動如有任何疑問，應諮詢證券經紀或其他註冊證券交易商、銀行經理、律 師、專業會計師或其他專業顧問。 閣下如已售出或轉讓所有名下梅斯健康控股有限公司股份，應立即將本通函及隨附之代表委任表格送交買主或 承讓人，或經手買賣之銀行、證券經紀或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示，概不對因本通函全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承 擔任何責任。 建議重選退任董事 及 建議授出一般授權以購回股份、發行新股份 及轉售庫存股份 及 建議續聘核數師 及 股東週年大會通告 本封面頁所用詞彙與本通函「釋義」一節所界定者具相同涵義。 梅斯健康控股有限公司謹訂於2025年6月30日（星期一）上午十時正假座中國上海市徐匯區宜山路光啟城辦公樓 1004舉行股東週年大會，股東週年大會通告載於本 ...

| 關於本報告 | 01 | | --- | --- | | 董事長致辭 | 03 | | 走進梅斯健康 | 05 | | 報告附錄 | 73 | | 夯實永續治理根基 | 13 | | --- | --- | | 公司治理 | 15 | | 合規經營與風險管理 | 17 | | 恪守商業道德 | 22 | | 數據與信息安全 | 24 | | 共築綠色發展未來 | 511 | 共享健康發展平台 | 61 L | | --- | --- | --- | --- | | 環境合規管理 | 53 | 員工權益保障 | 63 | | 應對氣候變化 | 54 | 健康與安全 | 67 | | 廢棄物管理 | 57 | 職業發展與培訓 | 67 | | 能源與水資源使用 | 58 | 社會公益 | 69 | | 綠色辦公 | ਦਰ | 醫療可及性 | 70 | | 行驅動 | 29 | | --- | --- | | 浅産保護 | 41 | | 質量與安全 | 42 | | 服務保障 | 45 | | 鏈管理 | 47 | 關於本報告 董事長致辭 走進梅斯健康 可持續發展管理 夯實永續治理根基 鑄就創新服務之心 共築綠 ...

Financial Performance - The company's total revenue for the year ended December 31, 2024, was approximately RMB 260.6 million, a decrease of about 25.4% compared to RMB 349.2 million in 2023[15]. - Gross profit for 2024 was RMB 162.2 million, down 25.1% year-on-year, while the gross margin increased by 0.2 percentage points[23]. - Net profit attributable to the company's owners for 2024 was approximately RMB 25.0 million, a decrease of 54.6% from RMB 55.0 million in 2023[16]. - The precision omnichannel marketing solutions segment generated revenue of RMB 115.1 million, accounting for 44.2% of total revenue, but decreased by 33.8% year-on-year[15]. - Revenue from the physician platform solutions for the year ended December 31, 2024, was approximately RMB 109.8 million, a year-on-year decrease of about 8.6% due to the impact of AI technology on certain product functionalities[28]. - RWS solutions revenue decreased by 35.4% year-on-year to approximately RMB 35.8 million due to prolonged project negotiation cycles and slow researcher recruitment[32]. - Total revenue for the reporting period decreased by 25.4% to approximately RMB 260.6 million, primarily due to increased compliance review times and reduced marketing budgets from pharmaceutical companies[41]. - Precision omnichannel marketing solutions revenue fell by 33.8% to approximately RMB 115.1 million, attributed to delayed order confirmations and significant demand drops from major clients[42]. - Physician platform solutions revenue decreased by 8.6% to approximately RMB 109.8 million, impacted by AI advancements allowing clients to complete certain functions independently[43]. Client and Market Engagement - The registered physician user base surpassed 3.33 million, covering 73% of physicians with deputy senior titles and above in China[9]. - The revenue retention rate for the top ten clients reached 100%, with a cumulative service count of 613 pharmaceutical and medical device companies[9]. - The company added 76 new domestic pharmaceutical clients, with inventory orders increasing by approximately RMB 61 million, reaching about RMB 142 million[31]. - The revenue retention rate for the top 10 clients was 100%, with 11 multinational pharmaceutical companies and 18 listed companies among the top 20 clients[31]. - The company provided medical solutions to 12 top-tier research hospitals in China, covering over 2,000 hospitals across various regions[22]. Technology and Innovation - The company has integrated AI technology into clinical trial design processes, significantly enhancing digital decision-making efficiency for medical institutions[9]. - The company plans to leverage its TriCura platform to integrate real-world data and AI technology, facilitating collaboration among healthcare providers, patients, and enterprises[11]. - The company is focusing on AI technology research and development to enhance service precision and operational efficiency, despite short-term cost increases[23]. - AI applications are expected to optimize clinical trial designs and improve market strategy precision, thereby increasing supply chain efficiency[39]. - The company is developing an intelligent decision-making system that covers research and development, supply chain, and marketing, aimed at improving industry efficiency[11]. Strategic Initiatives - The company completed the establishment of its Southeast Asia regional headquarters, laying the groundwork for supporting Chinese innovative pharmaceutical companies' international expansion[9]. - The company aims to establish a comprehensive service chain for pharmaceutical companies' international market entry, clinical support, and digital marketing[11]. - The company plans to establish a Southeast Asia headquarters in Singapore by 2025, focusing on the Vietnamese market and enhancing international competitiveness[37]. - The company aims to build a global medical industry ecosystem through a dual-driven model, facilitating the internationalization of pharmaceutical companies[37]. Governance and Compliance - The company is committed to enhancing its ESG strategy, focusing on environmental sustainability, compliance governance, and talent development[9]. - The board of directors did not recommend a final dividend for the year ended December 31, 2024[18]. - The company has adopted corporate governance codes and confirmed compliance with all applicable provisions as of December 31, 2024[68][76]. - The board consists of four executive directors, two non-executive directors, and three independent non-executive directors, ensuring a reasonable composition for the group's business nature[78]. - The board is responsible for approving significant transactions, including mid-term performance announcements and annual results, as well as authorizing mergers and acquisitions[84]. Employee and Operational Metrics - The total employee costs for the year ended December 31, 2024, were approximately RMB 168.7 million, down from approximately RMB 180.7 million in the same period of 2023[67]. - The company had a total of 488 full-time employees as of December 31, 2024, with 207 in platform operations and customer service, and 42 in research and development[67]. - Selling and distribution expenses decreased by approximately 12.9% from RMB 905 million for the year ending December 31, 2023, to approximately RMB 788 million for the year ending December 31, 2024, attributed to enhanced sales personnel efficiency[48]. - Research and development expenses decreased to approximately RMB 232 million for the year ending December 31, 2024, from RMB 166 million, mainly due to in-house production and the integration of AI tools[50]. Risk Management - The group faces significant risks related to regulatory compliance, data accuracy, and potential legal liabilities that could adversely affect business operations[144][147]. - The group has not identified any major non-compliance with relevant laws and regulations during the reporting period[142]. - The group is committed to maintaining a high level of data security and privacy, which may incur high compliance costs[147]. - The board believes that the risk management and internal control systems are adequate and effective for the fiscal year ending December 31, 2024[120]. Shareholder and Capital Management - The company has not entered into any significant contracts with its controlling shareholders or their subsidiaries during the reporting period[162]. - The company has not granted any rights to directors or their associates to acquire shares during the reporting period, except as disclosed in the annual report[160]. - The company has not participated in any arrangements that enable directors to obtain rights in any other legal entities during the reporting period[161]. - The company will not declare or pay any returns or benefits to shareholders without prior written consent from the foreign-invested enterprise[176].

Financial Performance - The total revenue for the year ended December 31, 2024, was approximately RMB 260.6 million, a decrease of about RMB 88.6 million or 25.4% compared to RMB 349.2 million for the year ended December 31, 2023[5]. - The net profit attributable to the owners of the parent company for the year ended December 31, 2024, was approximately RMB 25.0 million, a decrease of about RMB 30.1 million or 54.6% from RMB 55.0 million for the previous year[5]. - The gross profit for the year ended December 31, 2024, was RMB 162.2 million, down 25.1% year-on-year, while the gross margin increased by 0.2 percentage points[10]. - Total revenue for 2024 was RMB 260,623 thousand, a decrease of 25.4% compared to RMB 349,194 thousand in 2023[24]. - Gross profit for 2024 was RMB 162,174 thousand, down 25.2% from RMB 216,607 thousand in 2023[24]. - The total comprehensive income for 2024 was RMB 29,234 thousand, a decrease of 65.9% from RMB 85,579 thousand in 2023[25]. - The company reported a basic earnings per share of RMB 0.05 for 2024, down from RMB 0.11 in 2023[25]. - Profit before tax decreased from RMB 60.5 million to approximately RMB 25.5 million for the reporting period[69]. - Net profit decreased by approximately 54.6% from RMB 55.0 million for the year ended December 31, 2023, to about RMB 25.0 million for the year ending December 31, 2024, with a net profit margin decline from 15.8% to 9.6%[71][72]. Revenue Breakdown - Revenue breakdown for 2024 includes RMB 109,771,000 from physician platform solutions, RMB 115,097,000 from precision omnichannel marketing solutions, and RMB 35,755,000 from RWS solutions[40]. - Revenue from precision omnichannel marketing solutions was RMB 115.1 million, accounting for 44.2% of total revenue, but decreased by 33.8% year-on-year[4]. - Revenue from the physician platform solutions business was approximately RMB 109.8 million, a year-on-year decrease of about 8.6% due to AI advancements allowing clients to complete some functions independently[13]. - Revenue from RWS solutions dropped by approximately 35.4% to RMB 35.8 million in 2024, down from RMB 55.4 million in 2023, due to extended project negotiation cycles and slow researcher recruitment[61]. Membership and Client Base - The company accumulated over 5.28 million members by December 31, 2024, including 3.33 million registered doctors, forming a smart ecosystem centered on clinical research data and medical product knowledge[8]. - As of December 31, 2024, the platform has approximately 3.33 million registered physician users, with an average of about 3.0 million active users during the reporting period[12]. - The company added 76 new domestic pharmaceutical clients, with inventory orders increasing by approximately RMB 61 million to about RMB 142 million, and revenue from domestic pharmaceutical clients accounting for approximately 61%[17]. - The company has 613 active clients, including 492 core pharmaceutical, biotechnology, and medical device companies, with a 100% revenue retention rate among the top 10 clients[17]. Research and Development - R&D expenses decreased significantly to RMB 23,238 thousand in 2024 from RMB 39,855 thousand in 2023, a reduction of 41.8%[24]. - The group’s research and development expenses decreased significantly from RMB 39,855,000 in 2023 to RMB 23,238,000 in 2024, reflecting a reduction of approximately 42%[45]. - The company is strategically increasing investment in AI technology research and development, focusing on innovative applications in the medical field to enhance service precision and operational efficiency[10]. - The company focuses on research and development (R&D) in the field of artificial intelligence (AI) and real-world studies (RWS)[98]. Corporate Governance and Compliance - The company has adopted corporate governance codes and confirmed compliance with all applicable provisions for the year ended December 31, 2024[82]. - The audit committee, consisting of three independent non-executive directors, reviewed the consolidated financial statements for the year ended December 31, 2024[90]. - The company emphasizes the importance of compliance with the corporate governance code as per the listing rules[98]. Future Plans and Strategies - The company aims to restore project execution speed and accelerate future growth as compliance reviews are gradually completed and new standards are implemented[10]. - The company plans to establish a Southeast Asia headquarters in Singapore by 2025, focusing on the Vietnamese market[20]. - The company plans to gradually restore growth in revenue for precision omnichannel marketing solutions in 2025[58]. - The company is focusing on expanding cooperation with emerging clients to mitigate the impact of centralized procurement on overall revenue[58]. - The company aims to expand its market presence in mainland China, excluding Taiwan, Macau, and Hong Kong[97]. Financial Position and Assets - The total assets minus current liabilities for 2024 stood at RMB 1,169,895 thousand, an increase from RMB 1,121,023 thousand in 2023[26]. - Cash and cash equivalents decreased from RMB 628.6 million to approximately RMB 366.9 million as of December 31, 2024[74]. - The company had no bank borrowings or other interest-bearing debts as of December 31, 2024, resulting in a debt-to-equity ratio of zero[75][76]. - The company reported revenue from customer contracts of RMB 260,623,000 for the year ending December 31, 2024, a decrease from RMB 349,194,000 in 2023, representing a decline of approximately 25.3%[40]. Operational Efficiency - The company is focused on enhancing supply chain stability and optimizing service models through a closed-loop ecosystem[20]. - The TriCura platform aims to reduce data collection cycles to within 6 months through AI integration[21]. - Selling and distribution expenses decreased by approximately 12.9% from RMB 90.5 million to about RMB 78.8 million for the year ending December 31, 2024, due to improved sales personnel efficiency[65]. - Administrative expenses increased by approximately 8.5% from RMB 56.4 million to about RMB 61.2 million for the year ending December 31, 2024, primarily due to the realization of equity incentive funds[67]. Dividend Policy - The company does not recommend the distribution of a final dividend for the year ended December 31, 2024[7]. - The company did not recommend any interim or final dividends for the reporting period[48]. - The company did not recommend any final dividend for the year ended December 31, 2024, consistent with the previous year[92].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 （於開曼群島註冊成立之有限公司） （股份代號：2415） 股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 梅斯健康控股有限公司 董事會主席及執行董事 張發寶博士 內幕消息 盈利警告 本公告乃由梅斯健康控股有限公司（「本公司」，連同其附屬公司，「本集團」）根據香 港聯合交易所有限公司證券上市規則（「上市規則」）第13.09(2)(a)條及證券及期貨條 例（香港法例第571章）第XIVA部項下內幕消息條文（定義見上市規則）而作出。 本公司董事（「董事」）會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根 據其對本集團截至2024年12月31日止年度（「報告期間」）之未經審核綜合管理賬目之 初步評估及董事會現時可得之資料，預期報告期間的純利將較截至2023年12月31日 止年度（「相應期間」） ...

（於開曼群島註冊成立之有限公司） （股份代號：2415） 董事會會議日期 梅斯健康控股有限公司（「本公司」）董事會（「董事會」）兹通告，本公司謹定於2025年 3月28日（星期五）舉行董事會會議，以（其中包括）考慮及批准本公司連同其附屬公 司截至2024年12月31日止的經審核年度業績及其刊發，及審議派發末期股息（如有） 之建議，以及處理其他事項。 承董事會命 梅斯健康控股有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 主席及執行董事 張發寶博士 於本公告日期，董事會包括執行董事張發寶博士、李欣梅博士、王帥先生及程亮先 生；非執行董事王欣女士及閆盛楓先生；以及獨立非執行董事劉濤女士、余明陽先 生及劉耀坤先生。 香港，2025年3月18日 ...

梅斯健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈，由2025年 1月10日起，本公司於香港的主要營業地點的地址將更改為香港銅鑼灣希慎道33號 利園一期19樓1928室。 （於開曼群島註冊成立之有限公司） （股份代號：2415） 更改香港主要營業地點的地址 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 MedSci Healthcare Holdings Limited 梅斯健康控股有限公司 承董事會命 梅斯健康控股有限公司 董事會主席及執行董事 張發寶博士 於本公告日期，董事會包括執行董事張發寶博士、李欣梅博士、王帥先生及程亮先 生；非執行董事王欣女士及閆盛楓先生；以及獨立非執行董事劉濤女士、余明陽先 生及劉耀坤先生。 香港，2025年1月10日 ...

Membership and Network Expansion - As of June 30, 2024, the company has over 5.1 million members, including approximately 3.2 million registered physician members[7] - The company aims to expand its network by attracting more hospitals, experts, pharmaceutical companies, and researchers[7] - The company has provided medical solutions to 12 top-tier research hospitals in China, covering over 2,000 hospitals across first and second-tier cities, extending to county and grassroots medical institutions[7] Financial Performance - Total revenue for the six months ended June 30, 2024, was approximately RMB 110.7 million, with a year-on-year gross profit decline of about 23.1%[8] - For the six months ended June 30, 2024, the company's revenue was approximately RMB 110.7 million, a decrease of 26.9% compared to RMB 151.4 million for the same period in 2023[19] - The precision omnichannel marketing solutions revenue dropped by approximately 51.0% to RMB 41.9 million from RMB 85.5 million year-on-year[20] - The physician platform solutions revenue increased by approximately 25.9% to RMB 55.2 million from RMB 43.9 million year-on-year, driven by increased demand for clinical research services[21] - The real-world research solutions revenue was approximately RMB 13.6 million, a decline of 38.4% compared to RMB 22.0 million in the previous year[14] Profitability and Expenses - Gross profit decreased by approximately 23.1% from RMB 88.3 million for the six months ended June 30, 2023, to RMB 67.9 million for the same period in 2024, with a gross margin increase from 58.3% to 61.4%[26] - The company recorded a pre-tax loss of approximately RMB 0.2 million for the six months ended June 30, 2024, compared to a pre-tax profit of approximately RMB 12.9 million for the same period in 2023[34] - Net profit margin decreased from approximately 7.9% for the six months ended June 30, 2023, to approximately 0.2% for the same period in 2024[34] - Selling and distribution expenses decreased by approximately 23.9% from RMB 49.7 million for the six months ended June 30, 2023, to RMB 37.9 million for the same period in 2024[26] - Administrative expenses increased by approximately 12.7% from RMB 31.8 million for the six months ended June 30, 2023, to RMB 35.8 million for the same period in 2024, mainly due to expenses related to the equity incentive plan[29] Research and Development - The company has provided clinical research solutions to 108 hospitals and 302 departments, marking a new growth point for this business segment[9] - R&D expenses decreased by approximately 37.2% from RMB 19.1 million for the six months ended June 30, 2023, to RMB 12.0 million for the same period in 2024, attributed to the use of AI technology[30] - The company aims to enhance AI technology innovation and application to improve operational efficiency and explore international market opportunities[15] Compliance and Industry Trends - The company emphasizes the importance of compliance and academic rigor in the ongoing digital transformation of the pharmaceutical industry[7] - The company believes that recent healthcare anti-corruption policies will promote high-quality development in the Chinese pharmaceutical industry[7] - The company is leveraging advanced artificial intelligence technologies and strict compliance measures to adapt to industry changes and seize growth opportunities[7] Client and Market Dynamics - The total number of pharmaceutical and medical device companies served by the company reached 591 as of June 30, 2024[7] - The company had 563 active clients, including 477 core pharmaceutical, biotechnology, and medical device companies, with a 100% revenue retention rate from the top 10 clients[13] - The demand for evidence-driven precision marketing solutions remains strong, particularly with an increase in orders from domestic pharmaceutical companies[12] Cash Flow and Financial Position - As of June 30, 2024, the company had cash and cash equivalents of approximately RMB 341.4 million, down from RMB 628.6 million as of December 31, 2023[38] - The company had no bank borrowings or other interest-bearing debts as of June 30, 2024, resulting in a debt-to-equity ratio of zero[38] - The company recorded a foreign exchange gain of RMB 5,751,000 from the translation of financial statements for the six months ended June 30, 2024, compared to a gain of RMB 42,520,000 for the same period in 2023[84] Shareholder and Equity Information - As of June 30, 2024, Dr. Li Xinmei holds a 29.30% equity interest in the company, while Mr. Zhang Fabao holds a 23.21% equity interest[49] - The total number of shares issued as of June 30, 2024, is 607,170,950 shares, which is the basis for calculating the equity percentages[50] - The company has a share reward plan that includes 162,115 reward shares granted to Mr. Fan Jie[51] Employee and Management Compensation - Employee costs for the six months ended June 30, 2024, totaled approximately RMB 88.1 million, unchanged from the same period in 2023[39] - Total compensation for key management personnel in 2024 was RMB 18,010,000, compared to RMB 3,698,000 in 2023, reflecting a significant increase due to share-based payments[120] - The company has established a share incentive plan to reward employees for their contributions to the group's growth and development[112]